Home
Ole-Bjørn Tysnes's picture

Ole-Bjørn Tysnes

Professor
  • E-mailOle-Bjorn.Tysnes@uib.no
  • Phone+47 55 97 50 63
  • Visitor Address
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2024). Fatigue in Parkinson's Disease: A Proteomic Study of Cerebrospinal Fluid. Movement Disorders.
  • Show author(s) (2023). Seed Amplification Assay as a Diagnostic Tool in Newly-Diagnosed Parkinson's Disease. Journal of Parkinson's Disease. 841-844.
  • Show author(s) (2023). Inflammatory biomarkers in newly diagnosed patients with Parkinson’s disease and related neurodegenerative disorders. Neurology: Neuroimmunology and neuroinflammation.
  • Show author(s) (2023). Identification of diagnostic and prognostic biomarkers of PD using a multiplex proteomics approach. Neurobiology of Disease.
  • Show author(s) (2023). Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson's Disease Dementia. Movement Disorders Clinical Practice. 980-986.
  • Show author(s) (2023). Cognitive Profile in Parkinson’s Disease Dementia Patients with Low versus Normal Cerebrospinal Fluid Amyloid Beta. Dementia and Geriatric Cognitive Disorders Extra. 39-47.
  • Show author(s) (2022). Use of Off-Label Drugs and Nutrition Supplements among Patients with Amyotrophic Lateral Sclerosis in Norway. Neurology Research International. 1-6.
  • Show author(s) (2022). Ultra-deep whole genome bisulfite sequencing reveals a single methylation hotspot in human brain mitochondrial DNA. Epigenetics. 16 pages.
  • Show author(s) (2022). The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metabolism. 396-407.e6.
  • Show author(s) (2022). Severe Hyperhomocysteinemia in a Patient with Parkinson Disease. Clinical Chemistry. 396-401.
  • Show author(s) (2022). Parkinson’s disease clinical milestones and mortality. NPJ Parkinson's Disease.
  • Show author(s) (2022). Mitochondrial haplogroups and cognitive progression in Parkinson’s disease. Brain. 42-49.
  • Show author(s) (2022). Genetic Epidemiology of Amyotrophic lateral Sclerosis in Norway: A 2-Year Population-Based Study. Neuroepidemiology. 271-282.
  • Show author(s) (2022). GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study. Movement Disorders. 1016-1027.
  • Show author(s) (2022). Frailty in Parkinson's disease and its association with early dementia: A longitudinal study. Parkinsonism & Related Disorders. 51-57.
  • Show author(s) (2022). Early Forms of α-Synuclein Pathology Are Associated with Neuronal Complex I Deficiency in the Substantia Nigra of Individuals with Parkinson’s Disease. Biomolecules. 1-12.
  • Show author(s) (2022). Association of CSF Glucocerebrosidase Activity with the Risk of Incident Dementia in Patients with Parkinson Disease. Neurology. e388-e395.
  • Show author(s) (2021). Translation, cultural adaptation, and validation of a screening test for cognitive and behavioural changes in amyotrophic lateral sclerosis. Disability and Rehabilitation.
  • Show author(s) (2021). The impact of common genetic variants in cognitive decline in the first seven years of Parkinson's disease: A longitudinal observational study. Neuroscience Letters. 1-7.
  • Show author(s) (2021). NSAID use is not associated with Parkinson's disease incidence: A Norwegian Prescription Database study. PLOS ONE. 1-11.
  • Show author(s) (2021). Lack of Association between GBA Mutations and Motor Complications in European and American Parkinson's Disease Cohorts. Journal of Parkinson's Disease. 1569-1578.
  • Show author(s) (2021). Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. Nature Genetics. 787-793.
  • Show author(s) (2021). Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain. Molecular Neurodegeneration. 1-20.
  • Show author(s) (2021). Early constipation predicts faster dementia onset in Parkinson's disease. NPJ Parkinson's Disease. 1-7.
  • Show author(s) (2021). Association of SNCA Parkinson's Disease Risk Polymorphisms With Disease Progression in Newly Diagnosed Patients. Frontiers in Neurology. 1-7.
  • Show author(s) (2021). Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease. Neurology. e1036-e1044.
  • Show author(s) (2020). Validation of a UPDRS-/MDS-UPDRS-based definition of functional dependency for Parkinson's disease. Parkinsonism & Related Disorders. 49-53.
  • Show author(s) (2020). Progression of fatigue in Parkinson’s disease – a 9-year follow-up. European Journal of Neurology. 108-116.
  • Show author(s) (2020). Meta-analysis of whole-exome sequencing data from two independent cohorts finds no evidence for rare variant enrichment in Parkinson disease associated loci. PLOS ONE. 1-9.
  • Show author(s) (2020). Impulsive and compulsive behaviors in Parkinson's disease: Impact on quality of and satisfaction with life, and caregiver burden. Parkinsonism & Related Disorders. 27-30.
  • Show author(s) (2020). Genetic risk scores and hallucinations in patients with Parkinson disease. Neurology: Genetics. 9 pages.
  • Show author(s) (2020). Differential transcript usage in the Parkinson’s disease brain. PLoS Genetics. 1-24.
  • Show author(s) (2020). Differences in the presentation and progression of Parkinson's disease by sex. Movement Disorders. 1-14.
  • Show author(s) (2020). Common gene expression signatures in Parkinson’s disease are driven by changes in cell composition. Acta neuropathologica communications. 1-14.
  • Show author(s) (2019). The value of cerebrospinal fluid alpha-synuclein and the tau/alpha-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology. European Journal of Neurology. 43-50.
  • Show author(s) (2019). Orthostatic hypotension in Parkinson disease: A 7-year prospective population-based study. Neurology. e1526-e1534.
  • Show author(s) (2019). Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. Movement Disorders. 1839-1850.
  • Show author(s) (2019). Genetic risk of Parkinson disease and progression: An analysis of 13 longitudinal cohorts. Neurology: Genetics. 1-14.
  • Show author(s) (2019). Evolution of impulsive–compulsive behaviors and cognition in Parkinson’s disease. Journal of Neurology. 259-266.
  • Show author(s) (2019). Edinburgh Cognitive and Behavioral Amyotrophic Lateral Sclerosis Screen (ECAS) in Norway: Protocol for validation and a prospective cohort study. Contemporary Clinical Trials Communications. 1-7.
  • Show author(s) (2019). Combinatory microRNA serum signatures as classifiers of Parkinson's disease. Parkinsonism & Related Disorders. 202-210.
  • Show author(s) (2018). Ultradeep mapping of neuronal mitochondrial deletions in Parkinson's disease. Neurobiology of Aging. 120-127.
  • Show author(s) (2018). Rare genetic variation in mitochondrial pathways influences the risk for parkinson's disease. Movement Disorders. 1591-1600.
  • Show author(s) (2018). Laryngeal responses to mechanically assisted cough in progressing amyotrophic lateral sclerosis. Respiratory care. 538-549.
  • Show author(s) (2018). Inflammation and fatigue in early, untreated Parkinson's Disease. Acta Neurologica Scandinavica. 394-399.
  • Show author(s) (2018). Hyposmia in a simple smell test is associated with accelerated cognitive decline in early Parkinson's disease. Acta Neurologica Scandinavica. 508-514.
  • Show author(s) (2018). Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease. Parkinsonism & Related Disorders. 4-8.
  • Show author(s) (2018). Dopaminergic and opioid pathways associated with impulse control disorders in Parkinson's disease. Frontiers in Neurology. 1-9.
  • Show author(s) (2018). Association of glucocerebrosidase polymorphisms and mutations with dementia in incident Parkinson's disease. Alzheimer's & Dementia. 1293-1301.
  • Show author(s) (2018). Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulsory nationwide health registers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 303-310.
  • Show author(s) (2018). Alzheimer disease associated variants in SORL1 accelerate dementia development in Parkinson disease. Neuroscience Letters. 123-126.
  • Show author(s) (2018). A paradoxical relationship between family history, onset age, and genetic risk in Parkinson's disease. Movement Disorders. 298-299.
  • Show author(s) (2017). The natural history of depressive symptoms in patients with incident Parkinson?s disease: a prospective cohort study. Journal of Neurology. 1-8.
  • Show author(s) (2017). The GBA variant E326K is associated with Parkinson's disease and explains a genome-wide association signal. Neuroscience Letters. 48-52.
  • Show author(s) (2017). Neuronal complex I deficiency occurs throughout the Parkinson's disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage. Acta Neuropathologica. 409-425.
  • Show author(s) (2017). Natural course of mild cognitive impairment in Parkinson disease. Neurology. 767-774.
  • Show author(s) (2017). July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 471-474.
  • Show author(s) (2017). Is fatigue associated with cognitive dysfunction in early Parkinson's disease? Parkinsonism & Related Disorders. 87-91.
  • Show author(s) (2017). Impulsive and Compulsive Behaviors in Parkinson’s Disease: The Norwegian ParkWest Study. Journal of Parkinson's Disease. 183-191.
  • Show author(s) (2017). Familial aggregation of Parkinson's disease may affect progression of motor symptoms and dementia. Movement Disorders. 241-245.
  • Show author(s) (2017). Epidemiology of Parkinson's disease. Journal of Neural Transmission.
  • Show author(s) (2017). Development and validation of prognostic survival models in newly diagnosed Parkinson's disease. Movement Disorders. 108-116.
  • Show author(s) (2017). Clinical milestones in Parkinson's disease: A 7-year population-based incident cohort study. Parkinsonism & Related Disorders. 28-33.
  • Show author(s) (2017). Bruk av avansert behandling ved Parkinsons sykdom i Norge. Tidsskrift for Den norske legeforening. 619-623.
  • Show author(s) (2016). Validation of a new assay for α-synuclein detection in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine. 254-260.
  • Show author(s) (2016). Utredning ved mistenkt kronisk utmattelsessyndrom/ myalgisk encefalopati. Tidsskrift for Den norske legeforening. 227-232.
  • Show author(s) (2016). Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 256-264.
  • Show author(s) (2016). Risk and course of motor complications in a population-based incident Parkinson's disease cohort. Parkinsonism & Related Disorders. 48-53.
  • Show author(s) (2016). Reliability of three disability scales for detection of independence loss in Parkinson's Disease. Parkinson's Disease. 1-6.
  • Show author(s) (2016). Mortality trends of amyotrophic lateral sclerosis in Norway 1951–2014: an age–period–cohort study. Journal of Neurology. 1-8.
  • Show author(s) (2016). Loss of independence in early Parkinson disease: A 5-year population-based incident cohort study. Neurology. 1599-1606.
  • Show author(s) (2016). Long-term risk of falls in an incident Parkinson's disease cohort: the Norwegian ParkWest study. Journal of Neurology. 364-372.
  • Show author(s) (2016). Laryngeal response patterns influence the efficacy of mechanical assisted cough in amyotrophic lateral sclerosis. Thorax. 221-229.
  • Show author(s) (2016). Impact of Falls on Physical Activity in People with Parkinson's Disease. Journal of Parkinson's Disease. 175-182.
  • Show author(s) (2016). Fatigue in early Parkinson's disease: the Norwegian ParkWest study. European Journal of Neurology. 105-111.
  • Show author(s) (2016). Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nature Communications. 11 pages.
  • Show author(s) (2016). Changes in insomnia subtypes in early Parkinson disease. Neurology. 352-358.
  • Show author(s) (2015). The role of TREM2 R47H as a risk factor for Alzheimer’s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson’s disease. Alzheimer's & Dementia. 1407-1416.
  • Show author(s) (2015). HTRA2 p.G399S in Parkinson disease, essential tremor, and tremulous cervical dystonia. Proceedings of the National Academy of Sciences of the United States of America.
  • Show author(s) (2015). Fine mapping and resequencing of the PARK16 locus in Parkinson's disease. Journal of Human Genetics. 357-362.
  • Show author(s) (2015). Development of excessive daytime sleepiness in early Parkinson disease. Neurology. 162-168.
  • Show author(s) (2015). Association of a BACE1 gene polymorphism with Parkinson's disease in a Norwegian population. Parkinson's Disease. 5 pages.
  • Show author(s) (2014). The factor structure of the UPDRS motor scores changes during early Parkinson's disease. Parkinsonism & Related Disorders. 617-621.
  • Show author(s) (2014). Terapianbefaling Parkinsons sykdom. Nyhetsbulletin. 5-29.
  • Show author(s) (2014). Medisinering av Parkinsonpasienter som trenger kirurgisk behandling I generell anestesi. Nyhetsbulletin. 10-11.
  • Show author(s) (2014). CSF Aβ42 predicts early-onset dementia in Parkinson disease. Neurology. 1784-1790.
  • Show author(s) (2013). Verbal memory is associated with structural hippocampal changes in newly diagnosed Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry. 23-28.
  • Show author(s) (2013). Treatment in early Parkinson's disease: the Norwegian ParkWest study. Acta Neurologica Scandinavica. 107-113.
  • Show author(s) (2013). Supportive evidence for 11 loci from genome-wide association studies in Parkinson's disease. Neurobiology of Aging. 7 pages.
  • Show author(s) (2013). Prognosis of Mild Cognitive Impairment in Early Parkinson Disease. JAMA Neurology. 580-586.
  • Show author(s) (2013). Parkinson disease: Associated disorders in the Norwegian population based incident ParkWest study. Parkinsonism & Related Disorders. 53-55.
  • Show author(s) (2013). Laryngeal response patterns to mechanical insufflation-exsufflation in healthy subjects. American Journal of Physical Medicine & Rehabilitation. 920-929.
  • Show author(s) (2013). Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson's disease. Parkinsonism & Related Disorders. 1027-1032.
  • Show author(s) (2013). Cerebrospinal fluid amyloid-beta and phenotypic heterogeneity in de novo Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry. 537-543.
  • Show author(s) (2013). Cerebrospinal fluid A levels correlate with structural brain changes in Parkinson's disease. Movement Disorders. 302-310.
  • Show author(s) (2013). Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease. Acta Neurologica Scandinavica. 290-294.
  • Show author(s) (2012). White Matter Hyperintensities in Mild Lewy Body Dementia. Dementia and Geriatric Cognitive Disorders Extra. 481-495.
  • Show author(s) (2012). Subjective sleep problems in patients with early Parkinson's disease. European Journal of Neurology. 1575-1581.
  • Show author(s) (2012). Psychometric Properties of the Starkstein Apathy Scale in Patients With Early Untreated Parkinson Disease. The American journal of geriatric psychiatry. 142-148.
  • Show author(s) (2012). Number of CAG repeats in POLG1 and its association with Parkinson disease in the Norwegian population. Mitochondrion (Amsterdam. Print). 640-643.
  • Show author(s) (2012). Novel TARDBP mutations in Nordic ALS patients. Journal of Human Genetics. 316-319.
  • Show author(s) (2012). Multispectral MRI segmentation of age related white matter changes using a cascade of support vector machines. Journal of the Neurological Sciences. 211-216.
  • Show author(s) (2012). Hippocampal and ventricular changes in Parkinson's disease mild cognitive impairment. Neurobiology of Aging. 2113-2124.
  • Show author(s) (2012). Fatigue in early Parkinson's disease. Minor inconvenience or major distress? European Journal of Neurology. 963-968.
  • Show author(s) (2012). Comparing Hippocampal Atrophy in Alzheimer's Dementia and Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders. 44-50.
  • Show author(s) (2011). Verbal memory in drug-naive, newly diagnosed Parkinson's Disease. The retrieval deficit hypothesis revisited. Neuropsychology. 114-124.
  • Show author(s) (2011). Ventricular enlargement and mild cognitive impairment in early Parkinson's Disease. Movement Disorders. 297-301.
  • Show author(s) (2011). Increased risk of leg motor restlessness but not RLS in early Parkinson disease. Neurology. 1941-1946.
  • Show author(s) (2011). Autonomic and sensory symptoms and signs in incident, untreated Parkinson’s Disease : frequent but mild. Movement Disorders. 65-72.
  • Show author(s) (2011). Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Human Molecular Genetics. 1697-1700.
  • Show author(s) (2010). The role of APOE alleles in incident Parkinson's disease. The Norwegian ParkWest Study. Acta Neurologica Scandinavica. 438-441.
  • Show author(s) (2010). Gray matter correlations of cognition in incident Parkinson's disease. Movement Disorders. 629-633.
  • Show author(s) (2010). Differential Effect of Environmental Risk Factors on Postural Instability Gait Difficulties and Tremor Dominant Parkinson's Disease. Movement Disorders. 1847-1852.
  • Show author(s) (2010). Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson's disease: the Norwegian ParkWest study. Acta Neurologica Scandinavica. 418-424.
  • Show author(s) (2010). CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study. Journal of Neurology, Neurosurgery and Psychiatry. 1080-1086.
  • Show author(s) (2010). Apathy in drug-naïve patients with incident Parkinson's disease: the Norwegian ParkWest study. Journal of Neurology. 217-223.
  • Show author(s) (2009). White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. NeuroImage. 2083-2089.
  • Show author(s) (2009). The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry. 928-930.
  • Show author(s) (2009). Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study. Journal of Neurology, Neurosurgery and Psychiatry. 851-857.
  • Show author(s) (2009). High Prevalence of Orthostatic Hypotension in Mild Dementia. Dementia and Geriatric Cognitive Disorders. 307-313.
  • Show author(s) (2009). Cognitive impairment in incident, untreated Parkinson disease The Norwegian ParkWest Study. Neurology. 1121-1126.
  • Show author(s) (2009). Brain Atrophy and White Matter Hyperintensities in Early Parkinson's Disease. Movement Disorders. 2233-2241.
  • Show author(s) (2008). Treatment of sialorrhea in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica. 77-81.
  • Show author(s) (2007). Demens ved Parkinsons sykdom. Tidsskrift for Den norske legeforening. 2517-2520.
  • Show author(s) (2006). Bergen International symposium in neuroimmunology 2006. Introduction. Acta Neurologica Scandinavica, Supplementum. v-vi.
  • Show author(s) (2004). Neuroborreliosis with stroke-like manifestations. European Neurology. 49-50.
  • Show author(s) (2004). Epidemiology and management of ALS. Advances in Clinical Neuroscience & Rehabilitation. 8-9.
  • Show author(s) (2003). Risk of variant Creutzfeldt-Jakob disease and toncillectomy. Archives of Oto-Rhino-Laryngology. 141-144.
  • Show author(s) (2003). GM1-antibodies in post-polio syndrome and previous paralytic polio. Journal of Neuroimmunology. 141-144.
  • Show author(s) (2002). Kraniocervical arteriedisseksjon. Tidsskrift for Den norske legeforening. 2355-2357.
  • Show author(s) (2002). Etiologi og genetikk ved Alzheimers sykdom. Tidsskrift for Den norske legeforening. 50-53.
  • Show author(s) (2002). Cystic Dilatation of Virchow-Robin Spaces in the Midbrain. European Neurology. 186-188.
  • Show author(s) (2001). Hemiballisme ved hjerneinfarkt. Tidsskrift for Den norske legeforening. 2593-2595.
  • Show author(s) (2001). Epidemiology of ALS. Increasing incidence? Profile. 6-7.
  • Show author(s) (2000). Polynevropati er et tidlig funn ved primært systemisk amyloidose. Tidsskrift for Den norske legeforening. 1291-1293.
  • Show author(s) (2000). Polynevropati er et tidlig funn ved primært systemisk amyloidose. Tidsskrift for Den norske legeforening. 1291-1293.
  • Show author(s) (2000). Increasing mortality from amyotrophic lateral sclerosis in Norway? Neurology. 1262-1266.
  • Show author(s) (2000). Increasing mortality from amyotrophic lateral sclerosis in Norway? Neurology. 1262-1266.
  • Show author(s) (2000). Diffusjonsvektet magnetisk resonanstomografi - nytt i diagnostikken av Creutzfeldt-Jakob sykdom. Tidsskrift for Den norske legeforening. 675-677.
  • Show author(s) (2000). Diffusjonsvektet magnetisk resonanstomografi - nytt i diagnostikken av Creutzfeldt-Jakob sykdom. Tidsskrift for Den norske legeforening. 675-677.
  • Show author(s) (1999). Dolikoektasi av intrakraniale arterier og hjerneslag. Tidsskrift for Den norske legeforening. 3004-3005.
  • Show author(s) (1999). Combined effect of alkyl-lysophospholipid and vincristine on proliferation, migration and invasion in human glioma cell lines in vitro. Anticancer Research. 149-56.
  • Show author(s) (1998). Expression of annexin II in glioma cell lines and in brain tumor biopsies. Journal of Neuro-Oncology. 11-18.
  • Show author(s) (1998). Dynamic determination of human glioma invasion in vitro. Journal of Neurosurgery. 441-447.
  • Show author(s) (1998). Dynamic determination of human glioma invasion in vitro. Journal of Neurosurgery. 441-447.
  • Show author(s) (1997). Skrapesyke, kugalskap og Creutzfeldt-Jakobs sjukdom. Naturen. 81-90.
  • Show author(s) (1997). Fem års erfaringer med en amyotrofisk lateralsklerose klinikk. Tidsskrift for Den norske legeforening. 1892-1895.
  • Show author(s) (1997). En ny variant av Creutzfeldt-Jakobs sjukdom. Vil vi sjå utvikling av ein epidemi? Tidsskrift for Den norske legeforening. 384-388.
  • Show author(s) (1997). Adhesion and migration of glioma cells are differently dependent on extracellular matrix molecules. Anticancer Research. 1035-1043.
  • Show author(s) (1994). Varicella zoster-infeksjoner og neurologiske komplikasjoner. Tidsskrift for Den norske legeforening. 2484-2486.
  • Show author(s) (1994). Varicella zoster-infeksjoner og neurologiske komplikasjoner. Tidsskrift for Den norske legeforening. 2484-2486.
  • Show author(s) (1994). Varicella zoster-infeksjoner of neurologiske komplikasjoner. Tidsskrift for Den norske legeforening. 2484-2486.
  • Show author(s) (1994). Prognostic factors and survival in amyotrophic lateral sclerosis. Neuroepidemiology. 226-235.
  • Show author(s) (1994). Prognostic factors and survival in amyotrophic lateral sclerosis. Neuroepidemiology. 226-235.
  • Show author(s) (1994). Prognostic factors and survival in amyotrophic lateral sclerosis. Neuroepidemiology. 226-235.
  • Show author(s) (1994). Organic solvents activate human platelets through the inositol lipid-linked signal transduction system. Platelets. 266-271.
  • Show author(s) (1994). Organic solvents activate human platelets through the inositol lipid-linked signal tranduction system. Platelets. 266-271.
  • Show author(s) (1994). Hydrophobic organic solvents activate human platelets through inositol lipid metabolism. Platelets. 266-271.
  • Show author(s) (1994). Hydrophobic organic solvents activate human platelets in vitro. Platelets. 193-200.
  • Show author(s) (1994). Hydrophobic organic solvents activate human platelets in vitro. Platelets. 193-200.
  • Show author(s) (1994). Development of methionine dependence in a human glioma cell line. Relation to homocysteine remethylation and cobalamin status. Cancer Research. 4899-4906.
  • Show author(s) (1994). Development of methionine dependence in a human glioma cell line. Relation to homocystein remethylation and cobalamin status. Cancer Research. 4899-4906.
  • Show author(s) (1994). Anti-cardiac ryanodine receptor antibodies in thymoma-associated myasthenia gravis. Autoimmunity. 327-331.
  • Show author(s) (1994). Anti-cardiac ryanodine receptor antibodies in thymoma-associated myasthenia gravis. Autoimmunity. 327-331.
  • Show author(s) (1994). Activation of blood platelets in workers exposed to organic solvents. Platelets. 193-200.
  • Show author(s) (1993). The significance of radiologically diagnosed brain concussion for the outcome after head injury. Tidsskrift for Den norske legeforening. 1227-1229.
  • Show author(s) (1993). IgG subclass distribution of ryanodine receptor autoantibodies in patients with myasthenia gravis and thymoma. Journal of Autoimmunity. 507-515.
  • Show author(s) (1993). IgG subclass distribution of ryanodine receptor autoantibodies in patients with myasthenia gravis and thymoma. Journal of Autoimmunity. 507-515.
  • Show author(s) (1993). Differential effects of 12-O-tetradecanoyl-13-phorbol acetate (TPA) on growth, migration and invasion of a human glioma cell line. Anticancer Research. 1325-1330.
  • Show author(s) (1993). Differential effects of 12-O-tetradecanoyl-13-phorbol acetate (TPA) on growth, migration and invasion of a human glioma cell line. Anticancer Research. 1325-1330.
  • Show author(s) (1993). Betydningen av radiologisk påvist hjernekontusjon for resultatet av hodeskade. Tidsskrift for Den norske legeforening. 1227-1229.
  • Show author(s) (1992). Ryanodine Receptor Autoantibodies in Myasthenia Gravis Patients with a Thymoma. Annals of Neurology. 589-591.
  • Show author(s) (1992). Perifer facialisparese som symptom på infeksjon med Borrelia burgdorferi. Tidsskrift for Den norske legeforening. 50-51.
  • Show author(s) (1992). Inositol phospholipid metabolism in resting and stimulated human platelets. Cellular Signalling. 611-617.
  • Show author(s) (1992). Early and late outcome in head-injured patients with radiological evidence of brain damage. Comparison with patients substaining brain concussion. Acta Neurologica Scandinavica. 194-198.
  • Show author(s) (1992). Early and late outcome in head injury patients with radiological evidence of brain damage. Acta Neurologica Scandinavica. 194-198.
  • Show author(s) (1992). Activation of blood platelets in workers exposed to organic solvents. Journal of Occupational Medicine. 687-692.
  • Show author(s) (1992). Activation of blood platelets in workers exposed to organic solvents. Journal of Occupational Medicine. 687-692.
  • Show author(s) (1992). Activation of blood platelets in workers exposed to organic solvents. Journal of Occupational Medicine. 687-692.
  • Show author(s) (1992). Activation of blood platelets in workers exposed to organic solvents. Journal of Occupational Medicine. 687-692.
  • Show author(s) (1992). Activation of blood platelets in workers exposed to organic solvents. Journal of Occupational Medicine. 687-692.
  • Show author(s) (1992). Activation of blood platelets in workers exposed to organic solvents. Journal of Occupational Medicine. 687-692.
  • Show author(s) (1991). Stimulation of human platelets with low concentrations of thrombin: Evidence for equimolecular formation of inositol triphosphate and phosphatidic acid. International journal of biochemistry. 305-310.
  • Show author(s) (1991). Epidemiology of amytrophic lateral sclerosis in Hordaland County, western Norway. Acta Neurologica Scandinavica. 280-285.
  • Show author(s) (1991). Epidemiology of amyotrophic lateral sclerosis in Hordaland county, Western Norway. Acta Neurologica Scandinavica. 280-285.
  • Show author(s) (1991). Amyotrofisk lateral sklerose; forekomst og prognose. Tidsskrift for Den norske legeforening. 2634-2636.
Academic lecture
  • Show author(s) (2022). Reliabilitet ved oversatt norsk versjon av Edinburgh Cognitive and Behavioural ALS Screen (ECAS-N).
  • Show author(s) (2013). I hvilken grad vurderer Nevrologer førerkortforskriften likt.
  • Show author(s) (2013). Førerkortforskriften:Hva betyr de nye reglene for deg som nevrolog?
  • Show author(s) (2002). Do Riluzole or PEG affect survival in ALS.
Abstract
  • Show author(s) (2012). Impact of treatment on quality of life in early and drug-naive Parkinson's disease: the Norwegian ParkWest study. European Journal of Neurology. 58-58.
  • Show author(s) (2012). A Scandinavian multi-centre study replicates 11 susceptibility loci from genome-wide association studies in Parkinson's disease. European Journal of Neurology. 40-40.
Academic literature review
  • Show author(s) (2020). Targeting NAD+ in translational research to relieve diseases and conditions of metabolic stress and ageing. Mechanisms of Ageing and Development. 1-6.
  • Show author(s) (2014). Genetisk sammenheng mellom amyotrofisk lateral sklerose og frontotemporal demens. Tidsskrift for Den norske legeforening. 302-306.
  • Show author(s) (2010). Ny kunnskap om Creutzfeldt-Jakobs sykdom kan gi terapeutiske muligheter. Tidsskrift for Den norske legeforening. 601-604.
  • Show author(s) (2010). Are dysautonomic and sensory symptoms present in early Parkinson's disease? Acta Neurologica Scandinavica. 72-77.
  • Show author(s) (2009). Neurological examination of cortical function deficits. Acta Neurologica Scandinavica. 58-62.
  • Show author(s) (2004). Parkinsons sykdom: Nevroproteksjon ved COX 2 hemming? Nyhetsbulletin, Interessegruppen for Parkinsons sykdom i Norge. 7-8.
  • Show author(s) (2004). Nevroproteksjon av Coenzym Q10 ved Parkinsons sykdom. Nyhetsbulletin, Interessegruppen for Parkinsons sykdom i Norge. 9-10.
  • Show author(s) (2004). Fremtidsutsikter for PD-rammede. Parkinsonposten. 36-37.

More information in national current research information system (CRIStin)